Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

May 02, 2024 07:35 ET
CoreCard Corporation Reports First Quarter 2024 Results
CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the...
May 02, 2024 07:31 ET
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug...
May 02, 2024 07:30 ET
Parker Reports Fiscal 2024 Third Quarter Results
Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the fiscal 2024 third quarter ended March 31, 2024. Sales were $5.07 billion compared with $5.06 billion in the third quarter...
May 02, 2024 07:30 ET
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a...
May 02, 2024 07:30 ET
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s...
May 02, 2024 07:30 ET
AppTech Payments Corp. to Present at Sidoti Virtual Investor Conference May 8-9
AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce, announced Luke D’Angelo, Chairman & CEO, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference,...
May 02, 2024 07:30 ET
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV)...
May 02, 2024 07:30 ET
Biogen Reports Progress on Corporate Responsibility Priorities
Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders. “As we...
May 02, 2024 07:30 ET
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the first quarter ended March 31, 2024, and provided an...
May 02, 2024 07:30 ET
Clubhouse Media Group, Inc. Announces HoneyDrip.com Growth Results For April 2024
Clubhouse Media Group, Inc. (OTC: CMGR) ("CMGR"), a social media firm, today announced that HoneyDrip.com has seen month over month growth, continuing into April 2024. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a...
May 02, 2024 07:30 ET
Context Therapeutics Announces $100 Million Private Placement
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing...
May 02, 2024 07:30 ET
Fireweed Engages ICP Securities Inc. for Automated Market Making Services
FIREWEED METALS CORP. (“Fireweed” or the “Company”) (TSXV: FWZ; OTCQX: FWEDF; FSE: M0G) is pleased to announce that it has engaged the services of ICP Securities Inc. (“ICP”) to provide automated market making services, including use of its...
May 02, 2024 07:30 ET
FuelCell Energy and Toyota Motor North America Celebrate Launch of World's First "Tri-gen" Production System at the Port of Long Beach
FuelCell Energy, Inc. (Nasdaq: FCEL) and Toyota Motor North America, Inc. (Toyota) are celebrating the grand opening of the first-of-its-kind “Tri-gen” system at the Port of Long Beach, California, today. Tri-gen uses biogas to produce renewable...
May 02, 2024 07:30 ET
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
Guangzhou Bio-gene Technologies, a biotechnology company engaged in the discovery, development, and delivery of novel cell therapies for the treatment of blood malignancies and solid tumors, today announced that the first patient was treated with...
May 02, 2024 07:30 ET
GURU Organic Energy Enters Zero Sugar Segment With Metabolism-Boosting GURU Zero Wild Berry
GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand1, today announced the official launch of its new ZERO SUGAR category, starting with its mesmerizing GURU Zero Wild Berry. Carl...
May 02, 2024 07:30 ET
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a...
May 02, 2024 07:30 ET
Laureate Education Reports Financial Results for the First Quarter of 2024
Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the first quarter of 2024. First Quarter 2024 Highlights (compared to first quarter 2023):...
May 02, 2024 07:30 ET
MedBright AI Announces New Commercial Product Demos for MedMatrix AI Platform
MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) today announced MedMatrix, a product in which it has a significant investment, has launched two new demonstration videos highlighting the capabilities of...
May 02, 2024 07:30 ET
MGP Ingredients Reports First Quarter 2024 Results
MGP Ingredients, Inc. (Nasdaq: MGPI), a leading provider of branded and distilled spirits as well as food ingredient solutions, today reported results for the first quarter ended March 31, 2024. 2024 first quarter consolidated results compared to...
May 02, 2024 07:30 ET
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financial results on Thursday, May 9, 2024 prior to market opening. Following the release, Knight...